Groutropin 16 IU Dong-A ST Ko

Growth hormone, Groutropin 16 IU Dong-A ST Ko, is necessary for the normal development and growth of all organs and tissues in our body. It is secreted by the pituitary gland. The highest concentration of this substance in the blood is observed in childhood and adolescence, and then it begins to decrease. For athletes, this is a disadvantage, because low levels of growth hormone do not allow muscles to grow rapidly.

To overcome this problem, Groutropin 16 IU Dong-A ST Ko, a recombinant growth hormone with similar properties to natural growth hormone, is used.

Main positive effects of Groutropin 16 IU Dong-A ST Ko

The active ingredient of the drug is mainly used to increase muscle mass. It has anabolic and anti-catabolic properties, i.e. it causes muscle growth and at the same time slows down its degradation. The process takes place as organically as possible, so you can not expect a strong weight gain, but it will be tangible and noticeable.

In addition, the tool emphasizes the relief, forming a pronounced visibility of veins and muscle definition. The drug accumulates water in the cells, but does not cause swelling when used in the right dosage.

The effect of Groutropin 16 IU Dong-A ST Ko is known to strengthen bone tissue. The drug has a good effect on the condition of joints, cartilage and ligaments, reduces the risk of injury during training, so it is suitable for athletes who have problems in this area.

Fat burning is another effect of growth hormone, for which it is used in sports. Eliminating fat cells releases a lot of energy. The drug effectively removes belly fat and the person gets a more visible and beautiful relief.

Other effects of Groutropin 16 IU Dong-A ST Ko:

• body rejuvenation;
• strengthening of immunity;
• increase of blood sugar.

It is allowed for both men and women. Does not affect the work of sex hormones, does not cause gynecomastia in men and virilisation in women.

Possible side effects

Taking large doses has serious consequences. Unpleasant symptoms can occur at any time while taking the drug. These can be:

• swelling;
• hyperglycaemia;
• tunnel syndrome;
• muscle pain;
• high blood pressure.

Groutropin 16 IU Dong-A ST Ko should not be taken if a person has enlarged some organs and there are also neoplasms. Women during pregnancy and breastfeeding also cannot take it, as there is a risk of negative consequences for the child.

The hormone is taken only by those who have reached the age of majority, whose skeleton is already fully formed. On average, this is the age of 21 years, but the physical indicators of each individual are individual. Therefore, before using Groutropin 16 IU Dong-A ST Ko, you should consult a doctor.

Dosage and dosage rules

Groutropin 16 IU Dong-A ST Ko should be used in individual doses, depending on previous doping experience, physical performance and goals (fat burning, mass gain or other).

Frequency of reception – 3-4 times per week. It is enough to achieve the effect, but experienced athletes use the hormone more frequently. The best time to use it is before going to bed because growth hormone lowers the fatigue threshold. In addition, before bedtime also increases the natural level of Groutropin 16 IU Dong-A ST Ko in the body, so this intake programme will be as organic as possible.

The course can last from several weeks to several months, depending on the dosage and the athlete’s goals. It is therefore important to consult a sports physician who can help you develop the best regimen for you.

List of references

1. De León DD, Stanley CA. Mechanisms of Disease: Advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab. 2007;3(1):57-68. doi: 10.1038/ncpendmet0362.
2. Vasseur C, Rodien P. Genetic causes of isolated and combined pituitary hormone deficiency. Best Pract Res Clin Endocrinol Metab. 2011;25(4):361-375. doi: 10.1016/j.beem.2011.01.001.
3. Crowley WF Jr, Filicori M, Spratt DI, Santoro NF. The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Prog Horm Res. 1985;41:473-531.
4. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25(2):235-275. doi: 10.1210/er.2003-0002.
5. Weiss J, Axelrod L, Whitcomb RW, et al. Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. N Engl J Med. 1992;326(3):179-183. doi: 10.1056/NEJM199201163260305.